-
Article | 2020.10.14
Covid-19: A vaccine candidate using a lentiviral vector
This vaccine candidate for the SARS-CoV-2 virus, designed for nasal administration, demonstrated intense protection and extremely high production of antibodies and cytotoxic cell responses in preclinical trials.
-
News | 2021.07.15
BCG vaccine: the first tuberculosis vaccination took place a century ago
July 2021 marks the hundredth anniversary of the first vaccination of an infant with the BCG vaccine. Although tuberculosis is still one of the ten leading causes of mortality worldwide, this vaccine, developed at the Institut Pasteur, led to a steep reduction in the number of cases. We take a look back at how the vaccine was discovered.Albert Calmette arrived in Lille in 1897 as director of the...
-
News | 2023.11.15
The history of the first rabies vaccination in 1885
In 1885, a boy by the name of Joseph Meister was bitten 14 times by a rabid dog, with life-threatening consequences. Dr. Jacques Joseph Grancher convinced Louis Pasteur and his colleagues to vaccinate the young man. This first human rabies vaccination was a resounding success.
-
News | 2023.12.10
Diphtheria: A hundred years ago, the first toxoid vaccine
In 1923, veterinarian Gaston Ramon discovered the diphtheria toxoid, a molecule capable of neutralizing the toxin produced by diphtheria bacteria. Within a year he had conceptualized the notion of adjuvants and developed the forerunner of today's DTP vaccine. His discoveries would go on to save thousands of lives.
-
News | 2019.10.02
Lassa fever: vaccine set to be trialed
There is currently no vaccine for the Lassa arenavirus, which causes Lassa fever. This hemorrhagic fever, endemic in West Africa, infects up to 300,000 people each year. Given the urgency of the situation, scientists in the Biology of Viral Emerging Infections Unit and the Viral Genomics and Vaccination Unit at the Institut Pasteur evaluated the efficacy of several vaccine candidates. Following...
-
Document de presse | 2005.01.16
Cervical cancer : developing a therapeutic vaccine
A candidate vaccine for treating cervical cancers has just been proven effective in animals by researchers at the Institut Pasteur in cooperation with the French National Health and Medical Research Institute (Inserm) and the French National Center for Scientific Research (CNRS), and by the company BT PHARMA*, an Institut Pasteur start-up company. This therapeutic vaccine is directed against a...
-
Document de presse | 2006.03.22
Advances in research into a new tuberculosis vaccine
Researchers at the Pasteur Institute and the University of Zaragoza have developed a novel strategy to produce a new tuberculosis vaccine candidate. In an article published in Vaccine, they demonstrate that inactivation of a single gene in the tuberculosis bacillus gives rise to a strain that is more attenuated than BCG and which provides better protection against the disease. This work paves the...
-
Document de presse | 2005.01.05
A candidate Vaccine for West Nile Virus
Researchers at Institut Pasteur recently proved the efficacy of a candidate vaccine against West Nile virus infection in animal model. Their results are published in the Journal of Infectious Diseases. Mosquito-borne West Nile virus is an emerging neurotropic pathogen which is particularly disquieting due to its recent emergence in North America : since 2002, more than 13,000 cases, including 500...
-
Document de presse | 2021.05.12
An Asthma Vaccine Effective in Mice
Inserm teams led by Laurent Reber (Infinity, Toulouse) and Pierre Bruhns (Humoral Immunity, Institut Pasteur, Paris) and French company NEOVACS have developed a vaccine that could induce long-term protection against allergic asthma, reducing the severity of its symptoms and thus significantly improving patient quality of life. Their research in animals has been published in the journal Nature...
-
Document de presse | 2005.11.07
Malaria: an innovative approach for developing a vaccine
Researchers at the Institut Pasteur have developed a novel approach in order to design a vaccine candidate against malaria based on clinical observations in humans. Among populations infected by malaria, they sought to discover which antigens trigger immune responses capable of eliminating the Plasmodium falciparum parasite. In a phase I clinical trial, they showed that protective antibodies...